Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alexza partners Adasuve with Grupo Ferrer; sublicense to Medivir, AOP Orphan

Executive Summary

Alexza Pharmaceuticals Inc. (inhaled delivery systems for neurology drugs) has exclusively licensed its lead antipsychotic therapeutic Adasuve (loxapine; AZ004) to Grupo Ferrer Internacional SA, a private Spanish company that dedicates almost one-third of its portfolio to CNS products. Ferrer will have rights in Europe, Latin America, Russia, and the Commonwealth of Independent States.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register